ADVB

Advanced Biomed Inc.

$2.11

2.93%
SectorHealthcareIndustryDiagnostics & ResearchCountryUnited States

Advanced Biomed Inc., an investment holding company, engages in the research and development of microfluidic biochip technologies for precision oncology detection, diagnosis, and treatment in Taiwan. It offers A+Pre, a device that prepares blood samples for testing; the AC-1000, a device that separates cancer cells from the rest of the blood; A+SCDrop, a device that isolates individual cells; and A+CellScan, a device that stains and automatically counts cancer cells. The company provides developed dye kits used to identify different types of cancer cells. It also offers FinTruth financial verification agent platform, an enterprise AI financial verification platform designed to compare and verify financial analysis and AI-generated financial content against underlying source documents and financial rules, and to produce source-traceable and auditable results. The company was founded in 2014 and is based in Tsuen Wan, Hong Kong.

Source: Yahoo Finance
AI summary

Price & performance

1M-48.4%
3M-18.8%
YTD-34.1%
1Y-50.7%
52-week range—
Beta0.33
Full chart and returns against a benchmark

Q-Score

42/ 100

Quality against peers; 50 is the peer median.

Growth—
Risk27
Performance24
Valuation79
Profitability58
Leverage51
Sentiment—
Every score and metric

News sentiment

Open News

Latest results · FY 2026

Revenue$127.6K
Net income$6.7M
Net margin—
Historical fundamentals

Red flags in filings

3active red flags
Material weakness in controlsOct 13, 2026
Late filing noticeSep 28, 2026
Exchange listing noticeJan 21, 2026
Filings, findings and the timeline

Revenue exposure

0%of revenue from outside the US
United States100%
Regions, segments, customers and suppliers

Valuation

ADVBIndustryP/E0.5241.31P/S27.315.66EV/EBITDA—31.63P/B0.284.91PEG—3.59
Dividend yield0.00%
Every valuation metric